Due to the higher concentration of Chk1 gene expression and protein in SCLC compared to NSCLC, Chk1 inhibitors are a useful therapeutic agent in attempting to hinder this potent virulence mechanism in SCLC. This evidence concerns the gene CHEK1 and non-small cell lung carcinoma.